Immune evasion by dormant disseminated cancer cells: A Fermi paradox?

Anna Adam-Artigues; Luis E. Valencia Salazar; Julio A. Aguirre-Ghiso

doi:10.1016/j.ccell.2023.12.017

Immune evasion by dormant disseminated cancer cells: A Fermi paradox?

Anna Adam-Artigues
, Luis E. Valencia Salazar
, Julio A. Aguirre-Ghiso

Cell Biology

Research output: Contribution to journal › Comment/debate › peer-review

10 Scopus citations

Abstract

Rare disseminated tumor cells (DTCs) can persist after treatment in patients for years, and the immune system does not eliminate them. Goddard et al. propose that immune evasion by rare dormant DTCs is due to an improbability of contact imposed by large distances separating effector T cells and DTCs.

Original language	English (US)
Pages (from-to)	13-15
Number of pages	3
Journal	Cancer Cell
Volume	42
Issue number	1
DOIs	https://doi.org/10.1016/j.ccell.2023.12.017
State	Published - Jan 8 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ccell.2023.12.017

Cite this

@article{4474e452608f4760889f5e567a46f194,

title = "Immune evasion by dormant disseminated cancer cells: A Fermi paradox?",

abstract = "Rare disseminated tumor cells (DTCs) can persist after treatment in patients for years, and the immune system does not eliminate them. Goddard et al. propose that immune evasion by rare dormant DTCs is due to an improbability of contact imposed by large distances separating effector T cells and DTCs.",

author = "Anna Adam-Artigues and \{Valencia Salazar\}, \{Luis E.\} and Aguirre-Ghiso, \{Julio A.\}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2024",

month = jan,

day = "8",

doi = "10.1016/j.ccell.2023.12.017",

language = "English (US)",

volume = "42",

pages = "13--15",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Immune evasion by dormant disseminated cancer cells

T2 - A Fermi paradox?

AU - Adam-Artigues, Anna

AU - Valencia Salazar, Luis E.

AU - Aguirre-Ghiso, Julio A.

PY - 2024/1/8

Y1 - 2024/1/8

N2 - Rare disseminated tumor cells (DTCs) can persist after treatment in patients for years, and the immune system does not eliminate them. Goddard et al. propose that immune evasion by rare dormant DTCs is due to an improbability of contact imposed by large distances separating effector T cells and DTCs.

AB - Rare disseminated tumor cells (DTCs) can persist after treatment in patients for years, and the immune system does not eliminate them. Goddard et al. propose that immune evasion by rare dormant DTCs is due to an improbability of contact imposed by large distances separating effector T cells and DTCs.

UR - https://www.scopus.com/pages/publications/85181805061

UR - https://www.scopus.com/pages/publications/85181805061#tab=citedBy

U2 - 10.1016/j.ccell.2023.12.017

DO - 10.1016/j.ccell.2023.12.017

M3 - Comment/debate

C2 - 38194913

AN - SCOPUS:85181805061

SN - 1535-6108

VL - 42

SP - 13

EP - 15

JO - Cancer Cell

JF - Cancer Cell

IS - 1

ER -

Immune evasion by dormant disseminated cancer cells: A Fermi paradox?

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this